Measurement of Blood Lead by Immunoassay

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$75,000.00
Award Year:
1994
Program:
SBIR
Phase:
Phase I
Contract:
1 R43 ES06734-1,
Agency Tracking Number:
25048
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Bionebraska, Inc.
3940 Cornhusker Hwy, Ste 600, Lincoln, NE, 68504
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
Jay Stout
(402) 434-2466
Business Contact:
() -
Research Institution:
n/a
Abstract
Our company will develop an immunoassay that can be used in screening programs fordetermination of blood lead levels. Monoclonal antibodies specific for delta-aminolevulinic acid (ALAD)and lead will be used to investigate the feasibility of their use for detection of lead bound to ALAD inan erythrocyte lysate. The system will be evaluated first with purified ALAD containing known amountsof lead. An ALAD-specific antibody will be adsorbed to a solid phase and used to capture thelead-containing ALAD. The lead-specific antibody will then be used in an ELISA to quantify the amountof lead bound to the ALAD and compare the results to those obtained by atomic absorption. Aftersuccessful completion of these experiments, human blood samples containing known amounts of leadwill be substituted for the ALAD in the assay. Erythrocytes will be lysed with a nonionic detergent, andthe ALAD-specific antibody will be used to capture the released ALAD. The lead-specific antibody willthen be added for detection by ELISA of lead bound to ALAD. The results will be correlated with thelead concentrations in the blood samples determined by anodic stripping voltametry or graphite-furnaceatomic absorption.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government